Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EED | O75530 | 1/20 | 0.31 |
| ▸ | RBBP4 | Q09028 | 1/20 | 0.31 |
| ▸ | SUZ12 | Q15022 | 1/20 | 0.31 |
| ▸ | AEBP2 | Q6ZN18 | 1/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.31 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.31 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.31 |
| ▸ | ACACB | O00763 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7190206 | 0.88 | HDAC1 (0.32) | EEDRBBP4SUZ12AEBP2HDAC1 | |
| SCHEMBL7180723 | 0.86 | ACACB (0.33) | EEDRBBP4SUZ12AEBP2HDAC1 | |
| SCHEMBL7182332 | 0.85 | ULK1 (0.34) | — | |
| SCHEMBL7175539 | 0.85 | HDAC1 (0.31) | HDAC1HDAC2HDAC8 | |
| SCHEMBL7180819 | 0.84 | HDAC1 (0.34) | HDAC1HDAC2HDAC8ACACB | |
| Lithium SCHEMBL7180737 | 0.84 | ACACB (0.33) | EEDRBBP4SUZ12AEBP2HDAC1 | |
| SCHEMBL7183619 | 0.84 | — | — | |
| SCHEMBL7181311 | 0.83 | — | — | |
| SCHEMBL7184837 | 0.82 | ACACB (0.37) | HDAC1HDAC2HDAC8ACACB | |
| SCHEMBL7181198 | 0.81 | SMN1; SMN2 (0.36) | HDAC1HDAC2HDAC8ACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6579663-B2 | Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides | CIBA SPECIALTY CHEMICALS CORPORATION | 2003-06-17 | — | — | US | disclosed |
| US-20020107413-A1 | Organometallic monoacylarylphosphines | WOLF JEAN-PIERRE (CH) | 2002-08-08 | — | — | US | disclosed |
| US-6399805-B2 | SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES | CIBA SPECIALTY CHEMICALS CORPORATION | 2002-06-04 | — | — | US | disclosed |
| US-20010031898-A1 | Organometallic monoacylarylphosphines | CIBA SPECIALTY CHEMICALS CORP. | 2001-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020107413-A1 | Organometallic monoacylarylphosphines | CBR1, NAF1, DHCR24 | EED 3123/4885RBBP4 1533/4885SUZ12 455/4885 |
| US-20010031898-A1 | Organometallic monoacylarylphosphines | NAF1, DHCR24, CBR1 | EED 2750/4885RBBP4 1177/4885SUZ12 203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.